Across TCGA pan-cancer cohorts, CSN1S2AP RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of CSN1S2AP’s most consistent transcriptional readouts.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where CSN1S2AP RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CSN1S2AP is over-expressed in tumor.
LIHC are the cancer types where CSN1S2AP tumor–normal differential expression is most reproducible.